Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
Introduction and first reading, referred to
Email me when HF 4852 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track HF 4852. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill revises Minnesota’s drug formulary process by permitting members who may have a conflict of interest to participate in committee communications, while requiring them to recuse from voting on related matters. It obligates the Human Services commissioner to create a public comment system for formulary recommendations and forces the committee to seek advice from the Minnesota Rare Disease Advisory Council on orphan‑drug decisions. Additional changes cover committee makeup, disclosure, meeting frequency, honoraria, and prior‑authorization rules.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about HF 4852
3 free questions a day, no accountHistory
- Introduction and first reading, referred to Health Finance and Policy
Sponsors
- Reyer · sponsor
- Bierman
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when HF 4852 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track HF 4852 freeOr ask your AI assistant about HF 4852 directly:
Add to Claude, ChatGPT or Cursor